Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer
A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer
1 other identifier
interventional
2
1 country
1
Brief Summary
It is accepted that giving higher doses of chest radiation in as short a time span as possible improves chances of cure. In this study, the investigators propose to give an increased dose of chest radiotherapy for limited stage small cell lung cancer patients using a strategy of giving a slightly higher daily dose of radiotherapy than normal. The investigators hypothesize that our proposed chest radiotherapy dose will improve 2-year overall survival rates in patients with limited stage small cell lung cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
Started Jun 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 20, 2009
CompletedFirst Posted
Study publicly available on registry
May 22, 2009
CompletedStudy Start
First participant enrolled
June 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2011
CompletedFebruary 22, 2016
September 1, 2011
1.8 years
May 20, 2009
February 18, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
2-year overall survival
2011
Secondary Outcomes (2)
Quality of life
2011
Patterns of Failure
2011
Interventions
Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
Eligibility Criteria
You may qualify if:
- limited stage small cell lung cancer
- adequate pulmonary function test (FEV1 \>1.0 L, DLCO \>50%)
- signed study consent
- age at least 18 years
- Karnofsky performance status as least 70%
- eligible to receive standard concurrent small cell cancer chemotherapy
You may not qualify if:
- extensive stage disease
- mixed non small cell and small cell histology
- inadequate pulmonary function tests
- not eligible for concurrent chemotherapy
- subtotal or total tumor resection
- previous chest/neck radiotherapy
- prior or concurrent malignancy except non-melanomatous skin unless disease free for last 5 years
- pregnant
- prior chemotherapy for another malignancy
- patients with myocardial infarction within the preceding 6 months of symptomatic heart disease, including, angina, congestive heart failure, uncontrolled arrhythmias
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AHS Cancer Control Albertalead
- Cross Cancer Institutecollaborator
Study Sites (1)
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 20, 2009
First Posted
May 22, 2009
Study Start
June 1, 2009
Primary Completion
April 1, 2011
Study Completion
April 1, 2011
Last Updated
February 22, 2016
Record last verified: 2011-09